Showing Results for: “Glycemic Index and Diabetes”

First-of-Its-Kind Study Compares Open-Source Automated Insulin Delivery to Sensor-Augmented Pump Therapy Results from the CREATE Trial demonstrated open-source automated insulin delivery (AID) systems are a safe and effective therapy for people with type 1 diabetes. Findings from the randomized controlled trial (RCT) comparing open-source AID to sensor-augmented pump therapy (SAPT) were presented today at the 82nd Scientific Sessions of the American Diabetes Association ® (ADA). Open-source AID systems were developed to reduce the burden of living with diabetes by combining an insulin pump

Initial data indicate that children presented with higher acuity compared to the previous year New data show that the incidence and acuity of type 2 diabetes in children increased significantly during the peak of the COVID-19 pandemic, with more pediatric patients hospitalized from March to December 2020 compared to the same time period in 2019. Findings from the retrospective chart review were presented as a late-breaking poster session at the virtual 81st Scientific Sessions of the American Diabetes Association ® (ADA). Stay-at-home orders due to the COVID-19 pandemic exacerbated risk

Texas becomes 19th state to sign vital legislation to help insulin costs for those with diabetes Today, the American Diabetes Association ® (ADA) applauded a major victory secured for people with diabetes in Texas as Governor Greg Abbott signed legislation yesterday that will help make insulin more affordable for Texans on state-regulated health plans. The new law, created by Senate Bill 827 and supported by the ADA, limits cost-sharing to $25 per prescription for a 30-day supply of insulin, regardless of the amount or type of insulin needed. With the signing of this bill, Texas becomes the

Data Addresses Gaps in Preventive Prescriptions Therapy, Emphasizing the Importance of Multifaceted Interventions Today, findings from the COORDINATE-Diabetes trial demonstrated that multi-disciplinary care between cardiologists, diabetes specialists and other team members can significantly increase the prescriptions of evidence-based therapies to help treat patients with both type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD), commonly known as heart disease. The trial was presented as a late-breaking symposium today at the 83rd Scientific Sessions of the American

Reality show style competition showcases novel diabetes business ideas with potential funders as part of ADA 83 rd Scientific Sessions Today, the American Diabetes Association® (ADA) announced the winners of its inaugural pitch competition at the 83rd Scientific Sessions of the American Diabetes Association (ADA) in San Diego, CA. The first-ever Innovation Challenge highlighted six business concepts for diabetes care before a panel of potential funders, with the goal of connecting innovators and startup companies with transformative solutions and ideas. The winners, Minutia, Oregon Health &

American Diabetes Association Symposium Demonstrates Benefits of Once Weekly Drug for Weight Loss and Glycemic Control Today, findings from SURMOUNT-2, a study of tirzepatide in participants with type 2 diabetes who have obesity were announced, demonstrating more weight loss in individuals with diabetes than any other medication to date. The results were presented at the 83rd Scientific Sessions of the American Diabetes Association ® (ADA) in San Diego, CA and were simultaneously published in The Lancet . Obesity impacts 650 million people worldwide including nearly half of all Americans and

Today, the American Diabetes Association ® (ADA) announced a partnership with Elevance Health Foundation to improve health equity through the free-of-charge, enhanced What Can I Eat? (WCIE?) program, designed to address the social determinants of health that contribute to type 2 diabetes. Supported by the Elevance Health Foundation, this collaboration will deliver accessible nutrition education, free nutritious foods, and resources to underserved communities with type 2 diabetes in Indiana, New York, Ohio, and Virginia. Since 2016, the WCIE? program has focused on delivering nutrition

New legislation in Illinois to make insulin more affordable for all Illinoisans who need it Today, Illinois Governor J.B. Pritzker signed legislation that will cap insulin co-pays. Senate Bill 667 (SB 667) also requires the Illinois Department of Insurance to issue a report that includes a summary of insulin pricing practices as well as public policy recommendations to control and prevent overpricing of prescription insulin drugs made available to Illinois consumers. The American Diabetes Association (ADA) applauds Governor Pritzker and bill sponsors Senator Andy Manar and Representative Will

The Teplizumab Prevention Trial has given validity to the concept that immune therapy can delay the diagnosis of type 1 diabetes (T1D), according to findings presented at a symposium entitled “New Therapeutic Approaches and Insights for Type 1 Diabetes” today at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® at the Moscone Convention Center in San Francisco. Family members of someone with T1D have a 15 times greater risk of developing T1D than individuals from the general population. Testing can determine the presence of autoantibodies, indicating risk for T1D, and the

On May 22, 2019, Colorado Governor Jared Polis signed the first bill in the nation that will cap insulin co-pays at $100 per month, regardless of the number of vials needed. House Bill 1216: Reduce Insulin Prices, also enlists the Colorado Attorney General to investigate the rising price of insulin in Colorado and make recommendations to the General Assembly for further action. The American Diabetes Association (ADA) applauds Governor Polis and bill sponsors, Representative Dylan Roberts and Senators Kerry Donovan and Kevin Priola, for their leadership on this important legislation to reduce